

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA HEALTH

China Health Technology Group Holding Company Limited

中國健康科技集團控股有限公司

*(Incorporated in the Cayman Islands with limited liability and formerly known as
China Bozza Development Holdings Limited 中國寶沙發展控股有限公司)*

(Stock code: 1069)

TERMINATION OF VERY SUBSTANTIAL ACQUISITION IN RELATION TO THE ACQUISITION OF 52% EQUITY INTEREST IN THE TARGET COMPANY

References are made to the announcement of China Health Technology Group Holding Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 8 September 2023 regarding a very substantial acquisition in relation to the acquisition of 52% equity interest in the Target Company (the “**Announcement**”) and the announcements of the Group dated 29 September 2023, 1 November 2023, 31 January 2024 and 29 February 2024 in relation to the delay in despatch of circular. Unless otherwise defined, terms used herein shall bear the same meanings as defined in the Announcement.

THE TERMINATION AGREEMENT

After the Equity Sale and Purchase Agreement was signed, the Company has subsequently conducted detailed due diligence and other work on the Vendor. However, the Vendor was unable to provide satisfactory due diligence documents to the Company upon the Company’s request. Upon friendly negotiation between the Company and the Vendor, the parties decided to terminate the Acquisition.

The Board hereby announce that on 8 April 2024 (after trading hours), the Company, as purchaser, and the Vendor entered into a termination agreement (the “**Termination Agreement**”), pursuant to which both parties have irrevocably agreed to terminate the Equity Sale and Purchase Agreement with effect from the date of the Termination Agreement (save for the provisions relating to confidentiality which shall survive termination).

Pursuant to the Termination Agreement, save for the provisions relating to confidentiality, the respective responsibilities and obligations of both parties under the Equity Sale and Purchase Agreement shall be released, waived, revoked and terminated with effect from the date of the Termination Agreement and both parties irrevocably agreed not to pursue any past, existing and future claims or legal actions of any kind which any of the Company or the Vendor has or may have against the other in respect of the matters in connection with the Equity Sale and Purchase Agreement.

The Board considers that the Termination Agreement will not have any material adverse effect on the business, operations or financial position of the Group.

As the Acquisition has been terminated pursuant to the Termination Agreement, no circular would be despatched to the Shareholders and no EGM would be convened.

Shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company.

By Order of the Board
China Health Technology Group Holding Company Limited
Professor Fei Phillip
Chairman and Executive Director

Hong Kong, 8 April 2024

As at the date of this announcement, the Board comprises Professor Fei Phillip and Mr. Wang Yibin as the executive Directors; and Mr. Guo Zhonglong, Mr. Chau Wing Nam and Ms. Bu Xue as the independent non-executive Directors.